PCRX Company Profile and Key Details

PCRX has shown weak momentum, losing -15.83% over the past week and -15.61% over the past quarter, though year-to-date performance is down -25.43%. Short-term trend indicators are bullishly aligned (SMA20 3.41%, SMA50 -1.74%, SMA200 -5.58%). The stock’s 14-day RSI is 52.66 (neutral), while the ATR of 0.91 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -18.27% below its high and over 20.16% above its low. Average 10-day trading volume of 469.89 thousand shares is below the 3-month average of 546.56 thousand, indicating normal recent market interest.

Pacira BioSciences, Inc. has 39.86 million shares outstanding. The public float is 36.19 million shares, elevated short interest at 26.04% of float. This equals 7.21 million shares. The short ratio is 14.21 days. Institutional investors hold 117.36% of the float. Insiders own 1.77%. SLONIN JONATHAN holds 216.38 thousand shares, WILLIAMS KRISTEN has 167.06 thousand shares and STACK DAVID M has 153.78 thousand shares. Over the past six months, insider transactions show net selling. They sold 45.33 thousand shares across 8 transactions.

Pacira BioSciences, Inc. generated EPS of $0.45 over the past year. Five-year average earnings growth is -51.99%. Wall Street analysts project EPS growth of 6.33% annually over the next five years. The latest quarter delivered EPS of $0.73. The next quarter is forecast at $0.90. Next year's EPS is expected at $23.01. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 4 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $38.00 to $24.00. The high target offers 44.21% upside. The low target suggests -8.92% downside. The mean target is $30.73. This offers 16.62% upside. Pacira BioSciences, Inc. earnings surprise history is a mixed track record. The quarter that ended August 04, 2026, missed forecasts by 13.0%. The prior quarter beat by -87.23%. Over the last six quarters, Apple has recorded several small beats. These include 8.77% in May 08, 2025.

Pacira BioSciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $58.35. This means the shares are trading below this model’s fair value.

Pacira BioSciences, Inc. (NASDAQ:PCRX) closed at $26.35 USD, losing -$0.25 (-0.94%) from the previous close of $26.60. The stock is currently within 5% of its 52-week high $18.80 and $27.66. With a market capitalization of about $1.04 billion, Pacira BioSciences, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.27). Key stats such as the average daily volume over the past year has been around 563.94 thousand shares, in line with its 52-week average. Headquartered in Brisbane, CA, Pacira BioSciences, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Frank D. Lee, the company employs approximately 827 people and listed since February 03, 2011. Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health.

Pacira BioSciences, Inc. trades at a P/E ratio of 75.15, slightly above the S&P 500 average, with a price-to-sales ratio of 1.39 and a price-to-book ratio of 1.55 suggesting the stock is closer to book value. The P/FCF stands at 5.8, also above market averages.

Our AI price prediction model suggests that Pacira BioSciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.75%, with price expected at $28.92 by September 18, 2026, within a range of $27.78 to $30.04 3-Month Outlook: Projected fall of -16.66%, reaching $21.96 by December 03, 2026, with a range of $20.30 to $23.24. 1-Year Outlook: Projected gain of 0.49%, with price at $26.48 by September 03, 2027, within a range of $25.02 to $28.53.

Pacira BioSciences, Inc. (NASDAQ:PCRX) shares are down -25.43% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Pacira BioSciences, Inc. trading at a premium to the broader market with a P/E of 75.15. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $48.51, suggesting 84.1% upside. Our AI forecast model points to short-term strength (9.75% over two weeks), a medium-term fall (-16.66% over three months), and a longer-term gain (0.49% over one year), with expected trading ranges indicating moderate volatility.